HUP0103598A2 - Készítmények és eljárások WT1-specifikus immunterápiás alkalmazásra - Google Patents

Készítmények és eljárások WT1-specifikus immunterápiás alkalmazásra

Info

Publication number
HUP0103598A2
HUP0103598A2 HU0103598A HUP0103598A HUP0103598A2 HU P0103598 A2 HUP0103598 A2 HU P0103598A2 HU 0103598 A HU0103598 A HU 0103598A HU P0103598 A HUP0103598 A HU P0103598A HU P0103598 A2 HUP0103598 A2 HU P0103598A2
Authority
HU
Hungary
Prior art keywords
polypeptide
polypeptides
methods
cells
production
Prior art date
Application number
HU0103598A
Other languages
English (en)
Inventor
Alexander Gaiger
Original Assignee
Corixa Corporation
Alexander Gaiger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/164,223 external-priority patent/US7063854B1/en
Application filed by Corixa Corporation, Alexander Gaiger filed Critical Corixa Corporation
Publication of HUP0103598A2 publication Critical patent/HUP0103598A2/hu
Publication of HUP0103598A3 publication Critical patent/HUP0103598A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány tárgykörét malignus betegségek (pl. leukémia és rák)immunterápiája képezi. Közelebbről, a találmány tárgyát képezik a WT1-polipeptid immunogén részét tartalmazó polipeptidek, a találmányszerinti polipeptideket kódoló polinukleotidok, a WT1-polipeptidimmunogén részének utánzómolekulái, továbbá a találmány szerintipolipeptideket, az azokat kódoló polinukleotidokat, a találmányszerint utánzómolekulákat, WT1-polipeptidhez specifikusan kötődőantitesteket vagy T-sejteket, vagy WT1-polipeptidet termelőantigénprezentáló sejtet tartalmazó gyógyászati készítmények ésvakcinák. Szintén a találmány tárgyát képezi a WT1-polipeptidalkalmazása gyógyászati készítmények és vakcinák előállítására,valamint eljárások WT1-termelő sejtek csontvelőből vagy perifériásvérből történő előállítására. A találmány szerinti polipeptidek éskészítmények előnyösen alkalmazhatók a megnövekedett WT1-génexpresszióval jellemezhető malignus betegségekben szenvedőpáciensek kezelésére. Ó
HU0103598A 1998-09-30 1999-09-30 Compositions and methods for wt1 specific immunotherapy HUP0103598A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/164,223 US7063854B1 (en) 1998-09-30 1998-09-30 Composition and methods for WTI specific immunotherapy
US27648499A 1999-03-25 1999-03-25
PCT/US1999/022819 WO2000018795A2 (en) 1998-09-30 1999-09-30 Compositions and methods for wt1 specific immunotherapy

Publications (2)

Publication Number Publication Date
HUP0103598A2 true HUP0103598A2 (hu) 2002-01-28
HUP0103598A3 HUP0103598A3 (en) 2005-11-28

Family

ID=26860363

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103598A HUP0103598A3 (en) 1998-09-30 1999-09-30 Compositions and methods for wt1 specific immunotherapy

Country Status (25)

Country Link
EP (1) EP1117687B1 (hu)
JP (3) JP4243792B2 (hu)
KR (1) KR100752065B1 (hu)
CN (1) CN100486995C (hu)
AR (1) AR021849A1 (hu)
AT (1) ATE399179T1 (hu)
AU (1) AU6407899A (hu)
BR (1) BR9914116A (hu)
CA (1) CA2349442C (hu)
CZ (1) CZ20011144A3 (hu)
DE (1) DE69938970D1 (hu)
ES (1) ES2310052T3 (hu)
HK (1) HK1039782B (hu)
HU (1) HUP0103598A3 (hu)
IL (2) IL142216A0 (hu)
MX (1) MXPA01003344A (hu)
MY (1) MY139226A (hu)
NO (1) NO325839B1 (hu)
NZ (1) NZ510600A (hu)
PL (1) PL201881B1 (hu)
RU (1) RU2237674C2 (hu)
SA (1) SA00200872B1 (hu)
TR (1) TR200101482T2 (hu)
TW (1) TWI285648B (hu)
WO (1) WO2000018795A2 (hu)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
KR100767554B1 (ko) * 1998-07-31 2007-10-17 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 억제 유전자 더블유티1의 생산물에 기초한 암항원
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
AU7859900A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
JP2003524021A (ja) * 2000-02-22 2003-08-12 コリクサ コーポレイション 悪性中皮腫の診断および治療のための組成物および方法
JP4592641B2 (ja) * 2000-05-24 2010-12-01 治夫 杉山 Ｗｔ１関連疾患の検査方法
JP3846199B2 (ja) * 2000-05-24 2006-11-15 治夫 杉山 Ｗｔ１関連疾患の検査方法
EP1371664B1 (en) * 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
EP2014300B1 (en) * 2001-06-29 2011-01-12 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine comprising a cancer antigen based on the product of a tumor suppressor gene WT1 and a cationic liposome
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
JPWO2003028758A1 (ja) * 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
WO2003028757A1 (fr) * 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
CA2489227C (en) 2002-06-12 2012-03-13 Chugai Seiyaku Kabushiki Kaisha Hla-a24-restricted cancer antigen peptides
JP4611022B2 (ja) * 2002-09-12 2011-01-12 株式会社癌免疫研究所 癌抗原ペプチド製剤
DE60329201D1 (de) 2002-09-20 2009-10-22 Chugai Pharmaceutical Co Ltd Substituierte wt1-peptide
EP2154145B1 (en) * 2003-01-15 2013-04-24 International Institute of Cancer Immunology, Inc. Dimerized peptide
JP4566912B2 (ja) 2003-06-27 2010-10-20 株式会社癌免疫研究所 Ｗｔ１ワクチン適応患者の選択方法
CA2544214C (en) 2003-11-05 2018-08-28 International Institute Of Cancer Immunology, Inc. Hla-dr-binding antigen peptide derived from wt1
EP2186896B1 (en) 2004-03-31 2015-11-04 International Institute of Cancer Immunology, Inc. Cancer antigen peptides derived from WT1
EP1657250A1 (en) * 2004-11-11 2006-05-17 Charité - Universitätsmedizin Berlin HLA-A *01-binding T-cell epitope of WT1
WO2007063903A1 (ja) 2005-11-30 2007-06-07 International Institute Of Cancer Immunology, Inc. 新規ペプチド化合物
US8759483B2 (en) 2006-02-22 2014-06-24 International Institute Of Cancer Immunology, Inc. HLA-A* 3303-restricted WT1 peptide and pharmaceutical composition comprising the same
SG175566A1 (en) * 2006-10-17 2011-11-28 Oncotherapy Science Inc Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
CA2886622A1 (en) * 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
PL2119778T3 (pl) 2007-02-27 2016-04-29 Int Inst Cancer Immunology Inc Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie
CA2678404C (en) * 2007-02-28 2019-03-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
MX2009009589A (es) 2007-03-05 2009-09-21 Int Inst Cancer Immunology Inc Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos.
WO2009066462A1 (ja) * 2007-11-20 2009-05-28 Nec Corporation 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン
CN101888852B (zh) * 2007-12-05 2017-02-08 株式会社癌免疫研究所 癌症疫苗组合物
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
IN2011KN04700A (hu) * 2009-05-19 2015-07-10 Univ Miami
KR102171794B1 (ko) 2010-10-05 2020-10-29 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법
SG193956A1 (en) 2011-04-01 2013-11-29 Sloan Kettering Inst Cancer T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
EP3447140A3 (en) 2011-06-28 2019-05-29 International Institute of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific t cell
JP6163486B2 (ja) 2012-07-02 2017-07-12 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
SG11201504530VA (en) 2012-12-17 2015-07-30 Otsuka Pharma Co Ltd Method for activating helper t cell
JP6294868B2 (ja) 2013-03-12 2018-03-14 大日本住友製薬株式会社 液体水性組成物
JP5885885B2 (ja) 2013-03-29 2016-03-16 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
JP6671956B2 (ja) 2013-03-29 2020-03-25 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
CN105378479A (zh) * 2013-05-13 2016-03-02 株式会社癌免疫研究所 用于预测免疫疗法的临床效果的方法
CN106170297A (zh) * 2013-09-20 2016-11-30 纪念斯隆-凯特琳癌症中心 用于wt‑1‑阳性疾病的组合/辅助疗法
JP6005305B2 (ja) 2014-02-26 2016-10-12 テラ株式会社 Ｗｔ１抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤
KR20230141904A (ko) * 2014-12-11 2023-10-10 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 혈관 신생병의 면역 요법
CN108348552A (zh) * 2015-09-10 2018-07-31 纪念斯隆-凯特林癌症中心 通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法
EP4130026A1 (en) * 2015-11-20 2023-02-08 Memorial Sloan-Kettering Cancer Center Methods and compositions for treating cancer
CN105254760B (zh) * 2015-11-21 2018-08-17 福州迈新生物技术开发有限公司 一株分泌抗wt1蛋白的单克隆抗体及其应用
WO2018101309A1 (ja) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
EP3604325A4 (en) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. WT1 CANCER ANTIGEN PEPTIDE AND PEPTIDE CONJUGATE BODY WITH IT
MA49122A (fr) * 2017-04-10 2021-03-24 Immatics Biotechnologies Gmbh Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse
CN109758575B (zh) * 2018-02-14 2022-08-30 上海微球生物科技有限公司 充分多样的双亲性mhc ii结合多肽、免疫载体微球及其制备方法和应用
CN113382746A (zh) 2018-09-28 2021-09-10 大日本住友制药株式会社 注射用组合物
TW202045528A (zh) 2019-02-28 2020-12-16 日商大日本住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
KR20230009872A (ko) * 2020-05-12 2023-01-17 큐 바이오파마, 인크. 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
TW202200188A (zh) 2020-05-12 2022-01-01 日商大日本住友製藥股份有限公司 用以處置癌症之醫藥組合物
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
KR102476515B1 (ko) * 2020-09-11 2022-12-12 한국생명공학연구원 치주 질환 특이 항체 및 이의 용도
KR20220034563A (ko) * 2020-09-11 2022-03-18 한국생명공학연구원 신규 치주 질환 특이 항체 및 이의 용도
CA3228494A1 (en) 2021-08-12 2023-02-16 International Institute Of Cancer Immunology, Inc. Pharmaceutical composition and method for treating or preventing cancer
CN118076378A (zh) * 2021-09-24 2024-05-24 株式会社车疫苗研究所 包含肿瘤相关抗原衍生肽以及由脂肽和免疫活性物质组成的佐剂的抗癌疫苗组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007509A1 (en) * 1989-11-13 1991-05-30 Massachusetts Institute Of Technology Localization and characterization of the wilms's tumor gene
US5705159A (en) * 1993-08-31 1998-01-06 John Wayne Cancer Institute Immunoreactive peptide sequence from a 43 KD human cancer antigen
US5622835A (en) * 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
WO1999058135A1 (en) * 1998-05-11 1999-11-18 The Salk Institute For Biological Studies Compositions for the treatment of tumors, and uses thereof
KR100767554B1 (ko) * 1998-07-31 2007-10-17 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 억제 유전자 더블유티1의 생산물에 기초한 암항원

Also Published As

Publication number Publication date
BR9914116A (pt) 2002-01-15
KR100752065B1 (ko) 2007-08-28
WO2000018795A3 (en) 2000-10-26
IL142216A0 (en) 2002-03-10
CN1336935A (zh) 2002-02-20
IL142216A (en) 2009-06-15
CA2349442C (en) 2012-12-04
CZ20011144A3 (cs) 2002-06-12
MY139226A (en) 2009-08-28
TWI285648B (en) 2007-08-21
PL201881B1 (pl) 2009-05-29
HK1039782A1 (en) 2002-05-10
AR021849A1 (es) 2002-08-07
JP4235984B2 (ja) 2009-03-11
NO325839B1 (no) 2008-07-28
TW200606176A (en) 2006-02-16
WO2000018795A2 (en) 2000-04-06
JP2008069172A (ja) 2008-03-27
JP2007001984A (ja) 2007-01-11
TR200101482T2 (tr) 2002-01-21
AU6407899A (en) 2000-04-17
JP4243792B2 (ja) 2009-03-25
SA00200872B1 (ar) 2007-01-30
NZ510600A (en) 2003-12-19
DE69938970D1 (de) 2008-08-07
EP1117687A2 (en) 2001-07-25
RU2237674C2 (ru) 2004-10-10
CA2349442A1 (en) 2000-04-06
JP2002525099A (ja) 2002-08-13
NO20011613L (no) 2001-05-29
ATE399179T1 (de) 2008-07-15
NO20011613D0 (no) 2001-03-29
EP1117687B1 (en) 2008-06-25
WO2000018795A9 (en) 2000-08-31
PL348595A1 (en) 2002-06-03
CN100486995C (zh) 2009-05-13
ES2310052T3 (es) 2008-12-16
HK1039782B (zh) 2008-11-14
HUP0103598A3 (en) 2005-11-28
MXPA01003344A (es) 2004-04-21
KR20010085861A (ko) 2001-09-07

Similar Documents

Publication Publication Date Title
HUP0103598A2 (hu) Készítmények és eljárások WT1-specifikus immunterápiás alkalmazásra
US11555814B2 (en) Method for activation of helper t cell and composition for use in the method
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
HUP0103758A2 (hu) Neurotróf faktorok
HUP0101948A2 (hu) Il-2-szelektív agonisták és antagonisták
HUP0203035A2 (hu) Prosztatarák terápiájára és diagnózisára alkalmas vegyületek és eljárások
HUP0104717A2 (hu) Készítmények és eljárások petefészekrák terápiájára és diagnózisára
HUP0001153A2 (hu) Kémiailag módosított polipeptidek, eljárás ezek előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
EP0845032A4 (en) ISOLATED NUCLEIC ACID MOLECULES, PEPTIDES FORMING COMPLEXES WITH THE MOLECULE OF THE MAJOR HLA-A2 HISTOCOMPATIBILITY COMPLEX (MHC) AND THEIR APPLICATIONS
NO20004631L (no) Forbindelser og fremgangsmÕter for terapi og diagnose av lungekreft
HUP0301740A2 (hu) Emlőrák kezelésére és diagnosztizálására szolgáló készítmények és eljárások
HUP9903921A2 (hu) Tumor nekrózis faktorral rokon ligandum
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
WO2002088750A3 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
HUP9800377A1 (hu) Új növekedési faktor és ezt kódoló génszekvencia
HUP0300054A1 (hu) Daganatspecifikus állati fehérjék
GB0322645D0 (en) Use of antisecretory factor peptides
IL81221A0 (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for preparing said proteins and pharmaceutical compositions containing them
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
HUP0204216A2 (en) A new use of antibodies as vaccines
ATE371031T1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
ATE361359T1 (de) Funktion und aktivität des viralen proteins r (vpr)
NZ302821A (en) isolated truncated nucleic acid molecules which code for GAGE tumour rejection antigen precursors
HUP0402071A2 (hu) Csökkentett immunogenitású, módosított leptin

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees